Trial Search Results

Study to Examine the Effects of MultiStem in Ischemic Stroke

A study to examine the safety and potential effectiveness of the adult stem cell investigational product, MultiStem, in adults who have suffered an ischemic stroke. The hypothesis is that MultiStem will be safe and provide benefit following an ischemic stroke.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Athersys, Inc

Collaborator: Medpace, Inc.

Stanford Investigator(s):


  • Biological: MultiStem
  • Biological: Placebo


Phase 2


Inclusion Criteria:

   - Male or female subjects between 18 and 83 years of age (inclusive)

   - Clinical diagnosis of cortical cerebral ischemic stroke

   - Occurrence of a moderate to moderately severe stroke

Exclusion Criteria:

   - Presence of a lacunar or a brainstem infarct

   - Reduced level of consciousness

   - Major neurological event such as stroke or clinically significant head trauma within 6
   months of study

Ages Eligible for Study

18 Years - 83 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Neil Schwartz
Not Recruiting